Overview

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Status:
Completed

Trial end date:
2018-07-04

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the abuse potential of lemborexant (E2006) in comparison to placebo and 2 controls with known abuse potential (ie, zolpidem and suvorexant) with similar indications (zolpidem and suvorexant) or mechanisms of action (suvorexant).

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Purdue Pharma LP

Treatments:

Hypnotics and Sedatives
Lemborexant
Suvorexant
Zolpidem